Jefferies lowered the firm’s price target on Bicycle Therapeutics (BCYC) to $42 from $53 and keeps a Buy rating on the shares. For the FY24 updates, the company highlighted Zele+pembo Phase 1 data in 1L ulcerative colitis and Phase 2/3 Duravelo-2 dose selection data remains on track for the second half of the year, the analyst tells investors in a research note. The firm added that its new base case price target is discounted cash flow-based, adding that it assumes market entry for BT5528 in 2029 for the treatment of bladder cancer and ovarian cancer.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCYC:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue